Original Articles
Copyright ©The Author(s) 2001.
World J Gastroenterol. Apr 15, 2001; 7(2): 243-247
Published online Apr 15, 2001. doi: 10.3748/wjg.v7.i2.243
Table 1 Current status of the PRISMA study (initiation April 1998)
Endoscopy-histologically screened men between 55 and 65 years of ageCases (n = 1526)%
Presence of histological inclusion criterian = 27918.3
Patients randomizedn = 16758.8a
Non-randomized patients continuing follow-upn = 10939.1a
Patients with study endpoints31.8b
Cumulative follow-up (months/years)3046/253.8
Table 2 Currently conducted H. pylori-gastric cancer intervention trials with cancer endpoints
NameCountryTarget groupAge groupSample sizeMain endpoints
SCISCChinaPopulation30-652400Gastric cancer
NCIChinaPopulation35-693400Gastric cancer , dysplasia
JITHPJapanPopulation20-595000Gastric cancer
BUPAU.K.Population35-6956000Gastric cancer
PRISMA GermanyMale subjects55-653000Gastric cancer

  • Citation: Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, Luter J, Labenz J, Leodolter A, Malfertheiner P, Neubauer A, Ehninger G, Stolte M, rffer EB. Helicobacter pylori and gastric cancer: current status of the Austrain-Czech-German gastric cancer prevention trial (PRISMA-Study). World J Gastroenterol 2001; 7(2): 243-247
  • URL: https://www.wjgnet.com/1007-9327/full/v7/i2/243.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v7.i2.243